Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-...
Q1 2026
May 12, 2026
FY 2025
Mar 19, 2026
Q4 2025
Q3 2025
Nov 3, 2025
Q2 2025
Aug 12, 2025
